Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Development Of Synthetic Glycobiomarkers For The Follow-Up Of Chagas Disease Chemotherapy And Serological And Molecular Assays For Evaluation Of Trypanosoma Cruzi Infections In The U.S-Mexico Border, Igor L. Estevao
Open Access Theses & Dissertations
Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, affects 7-8 million people worldwide. Lately, the disease has been spread to nonendemic countries and regions, like the U.S. and Europe. The disease can be divided into two phases: the acute and chronic phases, which continue for years or even decades. There are two available drugs for CD treatment: benznidazole (BNZ) and nifurtimox (NFX). These drugs are highly effective in the acute phase but less efficient in the chronic stage. Other limitations of these drugs are their toxicity, leading to serious adverse events and premature treatment termination. Newer clinical trial …
Trypanosoma Cruzi Trypomastigote Glycosylphosphatidylinositol-Anchored Mucins And A Synthetic Alpha-Gal-Containing Neoglycoprotein As Potential Biomarkers And Vaccines For Chagas Disease, Igor Leandro Estevao
Trypanosoma Cruzi Trypomastigote Glycosylphosphatidylinositol-Anchored Mucins And A Synthetic Alpha-Gal-Containing Neoglycoprotein As Potential Biomarkers And Vaccines For Chagas Disease, Igor Leandro Estevao
Open Access Theses & Dissertations
Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a neglected tropical disease that kills or permanently disable thousands of people annually. About 6-8 million people are estimated to be infected worldwide. Although many efforts have been made for the development of an effective immunotherapy, currently there is no vaccine to prevent or treat CD in humans. Despite their toxicity, the two current drugs for CD, benznidazole (BZN) and nifurtimox (NFX), have medium-to-high efficacy in the chronic stage of the disease and could save or improve the lives of thousands of patients. However, negative seroconversion in treated patients, as …
Glycoconjugate-Based Vaccines For Chagas Disease, Brenda Guadalupe Zepeda
Glycoconjugate-Based Vaccines For Chagas Disease, Brenda Guadalupe Zepeda
Open Access Theses & Dissertations
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. About 6–8 million people are estimated to be infected worldwide. It is a blood borne pathogen and transmitted to humans by the insect vector (kissing bug), blood transfusion, organ transplant, contaminated foods and juices, and by congenital contagion. The chemotherapy is partially effective in chronic phase of the disease, and the drugs cause several side effects. There is no vaccine to prevent or treat Chagas disease. The great majority of experimental vaccines have employed whole parasite extracts, purified or recombinant proteins, synthetic peptides, or DNA; however, most of them provide …